(Q41573157)

4 October 2017

1 reference

title

Efficacy of specific immunotherapy in allergic asthma: myth or reality? (English)

1 reference

4 October 2017

1 reference

1 reference

Bonifazi F

1

1 reference

4 October 2017

Bilò MB

series ordinal

2

1 reference

4 October 2017

publication date

1 July 1997

1 reference

4 October 2017

1 reference

4 October 2017

volume

52

1 reference

4 October 2017

issue

7

1 reference

4 October 2017

page(s)

698-710

1 reference

Allergen immunotherapy in asthma: evidence for efficacy

4 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Mucosal inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Specific immunotherapy in asthma: is it effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Immunotherapy for mountain cedar pollinosis. A double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Ragweed immunotherapy in adult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Immunotherapy in cat-induced asthma *1Double-blind trial with evaluation of bronchial responses to cat allergen and histamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

House dust mite hyposensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

21 January 2018

Mortality from asthma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Sensitization to mite allergens is a risk factor for early and late onset of asthma and for persistence of asthmatic signs in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Sinus disease in children with respiratory allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

Dust mite allergens and asthma—A worldwide problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

SUBEPITHELIAL FIBROSIS IN THE BRONCHI OF ASTHMATICS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.1997.TB01226.X

10.1111/J.1398-9995.1997.TB01226.X

21 January 2018

Identifiers

DOI

1 reference

4 October 2017

1 reference